Skip to main content

FDA QMSR & 21 CFR Part 820: ISO 13485 Crosswalk

Last reviewed:

The FDA Quality Management System Regulation (QMSR) is the new quality management framework (QMS framework) for medical device and IVD manufacturers. QMSR replaced the Quality System Regulation (QSR) under 21 CFR Part 820 and took effect February 2, 2026.

Regulatory Overview

FDA QMSR is now in effect

The US Food and Drug Administration Quality Management System Regulation (QMSR) became effective on February 2, 2026. It amended the device current good manufacturing practice requirements in 21 CFR Part 820 and incorporated ISO 13485:2016 by reference, together with ISO 9000:2015 Clause 3 for terms and definitions. The former Quality System Regulation language should no longer be described as the current framework.

QMSR harmonizes much of FDA's system with the international medical device QMS standard, but it is not satisfied merely by holding an ISO 13485 certificate. Manufacturers remain responsible for the FDA-specific provisions in Part 820 and other applicable requirements, including complaint handling, Medical Device Reporting, corrections and removals, UDI, and records. FDA can inspect for compliance regardless of whether a certification body has issued a certificate.

What manufacturers should verify

A practical QMSR assessment should map the organization's procedures and records to the incorporated standard and FDA additions. Priority areas include:

  • risk-based quality planning across the product lifecycle;
  • design and development controls for applicable devices, including software validation;
  • supplier qualification and outsourced-process controls;
  • production, process validation, cleanliness, packaging, and labeling controls;
  • complaint investigation and escalation into MDR, corrections, removals, and CAPA;
  • management review, internal audits, quality records, and inspection readiness; and
  • controls for combination products and other product-specific requirements.

The assessment should be scoped to the legal manufacturer and each site or contractor performing regulated activities. Gaps need owners, evidence, and completion dates rather than a policy-only cross-reference.

FDA inspections under QMSR

FDA stopped using the Quality System Inspection Technique (QSIT) on February 2, 2026. Device inspections now use the process described in Compliance Program 7382.850. Records that previously received special limits under the former regulation, including management review, quality-audit, and supplier-audit reports, may be reviewed under QMSR. Inspection preparation should therefore include record availability, staff readiness, and evidence that the quality system operates in practice.

DHF, DMR and DHR under QMSR

The familiar Design History File (DHF), Device Master Record (DMR) and Device History Record (DHR) labels come from the former QSR. FDA's QMSR final rule, response to Comment 31 explains that their elements are largely covered by ISO 13485 documentation requirements, although the separate record-type terms were not retained. Removing a label does not remove the underlying evidence duty.

Historical recordCurrent documentation areaPractical handoff
DHF: design and development historyClause 7.3.10 design and development fileRetain or reference the records demonstrating applicable design and development compliance
DMR: approved specifications and proceduresClause 4.2.3 medical device fileConnect current product and manufacturing specifications to controlled documents
DHR: production history for a device or batchClause 7.5.1 device or batch recordRetain production, acceptance and traceability evidence for the released output

Treat this as an evidence crosswalk, not an instruction to rename three folders and declare compliance. Review content, references, approvals and access against the incorporated standard and FDA additions. Connect biocompatibility evaluations and other verification evidence to the design file, released specification and subsequent change assessments.

Maintaining compliance

QMSR work is not a one-time conversion project. New products, suppliers, sites, software releases, complaints, regulatory changes, and acquisitions can alter the compliance state. Manufacturers should incorporate QMSR impact checks into design changes, supplier changes, CAPA, management review, and internal-audit programs, and keep the FDA establishment, listing, submission, and post-market obligations aligned with the same controlled quality records.

QMSR and ISO 13485: a practical crosswalk

This planning map identifies evidence to inspect; it does not reproduce the licensed ISO standard or replace a clause-by-clause applicability assessment.

FDA provision or obligationISO 13485 area to mapPractical evidence
21 CFR 820.10: quality-management systemApplicable clauses 4–8Controlled scope, processes, risk-based controls and records showing implementation
820.10: design/development for covered devicesClause 7.3Design inputs/outputs, review, verification, validation, transfer and change records
820.10: UDI and other applicable FDA obligationsIdentification, traceability and regulatory processesUDI assignment controls and assessment of Parts 803, 806, 821 and 830 where applicable
820.35: additional record controlsRecords, complaints and servicingRequired device identification, complaint investigations and servicing information
820.45: labeling and packaging controlsProduction and product preservationRelease checks, labeling inspection, mix-up prevention and traceable acceptance evidence

FDA incorporates ISO 13485:2016; it does not replace every FDA-specific obligation with certification. Historical QSR references such as 820.30 or 820.100 may help trace old procedures, but should not be presented as the current QMSR section structure. Map the actual current provision and incorporated clause, then verify the operating records.

Connect complaint handling to Medical Device Reporting and corrections/removals assessments. Link the final marketed device to registration/listing and its authorized configuration. For an inspection finding, the Form 483 response guide explains how to turn individual corrections into documented systemic remediation.

Connect standards evidence and controlled labeling to the released device configuration.

For the detailed requirements mapping, use our Part 820 to ISO 13485 crosswalk.

Subscribe to newsletter
Subscribe to receive our monthly newsletter to your inbox.
By subscribing, you agree to our Terms and Conditions.
Thank you for subscribing!
Oops! Something went wrong while submitting the form.
United States registration starting at $1,000/year
AI-powered dossier compilation and local representation, all for a flat annual fee.
Get an estimate
How We Can Help

Strengthen FDA QMSR compliance with Pure Global

Plan your device registration, local representation and ongoing compliance with Pure Global.

Pure Global market entry support team

Frequently asked questions

Single Process,
Multiple Markets

When you partner with Pure Global, a single registration process opens doors to multiple countries. Our global subsidiaries make this streamlined path possible.

Let's Talk,
Anywhere You Are.

Whether looking for more information or ready to partner with us, we're here to guide you through every step of the regulatory process.

Contact us